TRANSMEDICS GROUP INC (TMDX)       74.69  -1.18 (-1.56%)

74.69  -1.18 (-1.56%)

US89377M1099 - Common Stock - After market: 74.69 0 (0%)

TRANSMEDICS GROUP INC74.69

NASDAQ:TMDX (3/28/2023, 7:00:02 PM)-1.18 (-1.56%)

After market: 74.69 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)02-22 2023-02-22/amc
Earnings (Next)05-01 2023-05-01/amc
Ins Owners2.93%
Inst Owners90.7%
Market Cap2.40B
Shares32.20M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts83.64
IPO05-02 2019-05-02

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

TMDX Daily chart

Company Profile

TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 212 full-time employees. The company went IPO on 2019-05-02. The firm is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The firm has designed and developed an organ care system (OCS), a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. The company designed its OCS technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state. The company has developed three OCS products, one each for lung, heart and liver transplantation. Its products include OCS Lung, OCS Heart, and OCS Liver. Its OCS product consists of three components customized for each organ, which include the OCS Console, OCS Perfusion Set and OCS Solutions. The company is also developing OCS products for additional organs, including kidneys.

Company Info

TRANSMEDICS GROUP INC

200 Minuteman Road

Andover MASSACHUSETTS 01810

P: 19785520900.0

CEO: Waleed H. Hassanein

Employees: 212

Website: https://www.transmedics.com/

TMDX News

News Image8 days ago - The Motley FoolWant $1 Million in Retirement? Invest $100,000 in These 3 Stocks and Wait 10 Years

Patient investors who would like to see their investments rise 10x have some interesting options right now.

News Imagea month ago - TransMedics Group, Inc.TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients...

News Imagea month ago - The Motley FoolIs TransMedics a Good Stock to Buy Right Now?

This is more than just a medical device manufacturer.

News Imagea month ago - The Motley FoolWhy TransMedics Stock Was a Big Star This Week

There was much for investors to like in the company's latest earnings report.

News Imagea month ago - TransMedics Group, Inc.TransMedics Reports Fourth Quarter and Full Year 2022 Financial Results

/PRNewswire/ - TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients...

News Imagea month ago - TransMedicsTransMedics to Present at Upcoming March Investor Conferences

TMDX Twits

Here you can normally see the latest stock twits on TMDX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example